Sol-Gel Technologies Ltd.
A maker of topical creams for skin conditions, this Israeli pharmaceutical company develops treatments for acne, rosacea, and rare diseases like Gorlin syndrome, using a silica-based technology that releases active ingredients slowly through the skin. Founded in 1997 by Dr. Alon Seri-Levy in Ness Ziona, it takes its unusual name from the sol-gel process—the chemical method behind its microencapsulation technology, where a liquid "sol" turns into a "gel." Its approved products include Twyneo for acne and Epsolay for rosacea.
Bought 137.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% owner · 27 transactions | — | 505.0K | — | 137.4K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +137.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.